Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
High Point, NC
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Kinston, NC
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Kinston, NC
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Salisbury, NC
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Cincinnati, OH
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Franklin, OH
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Franklin, OH
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Mentor, OH
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Mentor, OH
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Levittown, PA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Levittown, PA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Anderson, SC
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Anderson, SC
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Germantown, TN
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Jackson, TN
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Kingsport, TN
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Arlington, TX
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Houston, TX
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Logan, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Logan, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Ogden, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Sandy, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Sandy, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Lynchburgh, VA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Lynchburgh, VA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Seattle, WA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
mi
from
Spokane, WA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
mi
from
Ceske Budejovice,
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
mi
from
Ceske Budejovice,
Click here to add this to my saved trials
A PK and Safety Study in Subjects With Hepatic Impairment
A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  5/19/2016
Trius Investigator Site 001
mi
from
Orlando, FL
A PK and Safety Study in Subjects With Hepatic Impairment
A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 5/19/2016
Trius Investigator Site 001
mi
from
Orlando, FL
Click here to add this to my saved trials
A PK and Safety Study in Subjects With Hepatic Impairment
A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  5/19/2016
Trius investigator site 153
mi
from
Minneapolis, MN
A PK and Safety Study in Subjects With Hepatic Impairment
A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 5/19/2016
Trius investigator site 153
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated:  5/23/2016
NIH
mi
from
Bethesda, MD
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated: 5/23/2016
NIH
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated:  5/23/2016
Metropolitian Gastroenterology Group
mi
from
Chevy Chase, MD
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated: 5/23/2016
Metropolitian Gastroenterology Group
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated:  5/23/2016
Morristown Memorial Hospital
mi
from
Morristown, NJ
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated: 5/23/2016
Morristown Memorial Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated:  5/23/2016
Mount Sinai Hospital
mi
from
New York, NY
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated: 5/23/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated:  5/23/2016
General Hospital of Vienna
mi
from
Vienna,
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
Status: Enrolling
Updated: 5/23/2016
General Hospital of Vienna
mi
from
Vienna,
Click here to add this to my saved trials
Calcitonin for Treating X-linked Hypophosphatemia
Calcitonin for Treating X-linked Hypophosphatemia
Status: Enrolling
Updated:  5/24/2016
Yale School of Medicine
mi
from
New Haven, CT
Calcitonin for Treating X-linked Hypophosphatemia
Calcitonin for Treating X-linked Hypophosphatemia
Status: Enrolling
Updated: 5/24/2016
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
Status: Enrolling
Updated:  5/25/2016
University Hospital
mi
from
Columbia, MO
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed
Status: Enrolling
Updated: 5/25/2016
University Hospital
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Community Clinical Trials
mi
from
Orange, CA
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Community Clinical Trials
mi
from
Orange, CA
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
GastroDiagnostics
mi
from
Orange, CA
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
GastroDiagnostics
mi
from
Orange, CA
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Clinical Research of the Rockies
mi
from
LaFayette, CO
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Clinical Research of the Rockies
mi
from
LaFayette, CO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Florida Center for Gastroenterology
mi
from
Largo, FL
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Florida Center for Gastroenterology
mi
from
Largo, FL
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Internal Medicine Specialists
mi
from
Orlando, FL
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Internal Medicine Specialists
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Iowa Digestive Disease Center
mi
from
Clive, IA
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Iowa Digestive Disease Center
mi
from
Clive, IA
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Center for Digestive Health
mi
from
Troy, MI
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Surgical Centers of Michigan
mi
from
Troy, MI
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Surgical Centers of Michigan
mi
from
Troy, MI
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Center for Advanced Medicine
mi
from
Saint Louis, MO
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Center for Advanced Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Albany Medical College
mi
from
Albany, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
New York Hospital- Queens
mi
from
Flushing, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
New York Hospital- Queens
mi
from
Flushing, NY
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Long Island Clinical Research Associates, LLP
mi
from
Great Neck, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Long Island Clinical Research Associates, LLP
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Lenox Hill Endoscopy Center
mi
from
New York, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Lenox Hill Endoscopy Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Synergy First
mi
from
New York, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Synergy First
mi
from
New York, NY
Click here to add this to my saved trials
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated:  5/31/2016
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
A Study To Monitor Long-Term Treatment With PF-00547659
A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)
Status: Enrolling
Updated: 5/31/2016
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials